Valiant Organics to start production of OAP and Pharma Intermediates
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.
Health resources – both human and material are precious assets to the society and a robust health care administration and management system ensures their effective utilization: Dr Bharati Pravin Pawar
The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.
Steps afoot to make RRIH & RRIUM as a Centres of Excellence for Allergic Disorder and for Regimental Therapy respectively
Pawar also unveiled the India Family Planning 2030 vision document and launched the Medical Eligibility Criteria (MEC) Wheel Application, E-Module of Family Planning Logistics Management System (FPLMIS) and Digital Archive on Family Planning under the category of Digital Intervention.
Subscribe To Our Newsletter & Stay Updated